Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Transfusion Dependent Thalassaemia Management Market Snapshot (2023 to 2033)

The global Transfusion Dependent Thalassaemia Management Market is expected to garner a market value of US$ 10 Million in 2023 and is expected to accumulate a market value of US$ 17.91 Million by registering a CAGR of 6% in the forecast period 2023 to 2033. The market for Transfusion Dependent Thalassaemia Management registered a CAGR of 4% in the historical period 2018 to 2022.

Studies state that Thalassemia affects approximately 4.4 out of every 10,000 live births throughout the world. This condition causes both males and females to inherit the relevant gene mutations equally because it follows an autosomal pattern of inheritance with no preference for gender.

Report Attribute Details
Expected Market Value (2023) US$ 10 Million
Anticipated Forecast Value (2033) US$ 17.91 Million
Projected Growth Rate (2023 to 2033) 6% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Transfusion Dependent Thalassaemia Management Market Demand Analysis vs. Forecast 2023 to 2033

According to market research and competitive intelligence provider Future Market Insights- the market for Transfusion Dependent Thalassaemia Management reflected a value of 4% during the historical period, 2018 to 2022.

A series of international-level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering effective ways for Transfusion Dependent Thalassaemia Management.

According to the National Center on Birth Defects and Developmental Disabilities, thalassemia affects at least 1,000 people in the United States of America. The market's growth is also attributed to the factors such as growing disease prevalence, a rise in lifestyle-associated concerns, and technological advancements. Furthermore, the increasing incidence of thalassemia patients and increasing research and development investments are propelling immense growth.

In its new study, ESOMAR-certified market research and consulting firm Future Market Insights (FMI) offers insights into key factors driving demand for Transfusion Dependent Thalassaemia Management. In the years to come, increasing focus by government organizations and private agencies like WHO and pharmaceutical companies to create awareness of thalassemia is fuelling market growth. Thus, the market for Transfusion Dependent Thalassaemia Management is expected to register a CAGR of 6% in the forecast period 2023 to 2033.

Which are Some Prominent Drivers of the Transfusion Dependent Thalassaemia Management Market?

Increased Prevalence of the Condition to Push the Market Growth

According to the Thalassemia International Federation, approximately 7.0% of the global population suffers from diseases and conditions associated with hemoglobin, out of which around 70.0% have sickle cell anemia and the remaining develop thalassemia or other blood disorders. Around 2.1% of the global population is living with various forms of thalassemia. This disorder affects approximately 4.4 in every 10,000 live births worldwide.

Blood transfusion is one of the conventional treatments for thalassemia patients involving patients that need more than 2 units of red blood cells every 28 days. Furthermore, the growing investments in research and development programs by biotechnology and pharmaceutical companies are boosting market growth. Government measures to raise thalassemia awareness are also expected to propel the market in the next few years.

For instance, in March 2022, CIL inked an MoU with the Kokilaben Dhirubhai Ambani for its primary program Thalassemia Bal Seva Yojana, which would fund bone marrow transplants for Thalassemia and Aplastic Anaemia patients from low-income families. This initiative gives financial support of up to ten lakh rupees to children of low-income families suffering from Thalassemia and Aplastic Anaemia. This, in turn, is expected to have a significantly positive impact on the market's growth.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Faced by the Transfusion Dependent Thalassaemia Management Market?

Expensive Cost of Treatment to restrict Market Growth

According to the Centers for Disease Control, people who receive a lot of blood transfusions are at risk for iron overload. Red blood cells contain a lot of iron, and over time, the iron from all of the transfusions can build up in the body. When it builds up, the iron collects in places like the heart, liver, and brain, and can make it hard for these organs to work properly. To prevent iron overload, people with thalassemia may need chelation therapy, which is when doctors give a medicine - either a pill or a shot under the skin - to remove excess iron before it builds up in the organs. Considering this, the market growth is projected to get hampered.

The expensive treatment of Transfusion Dependent Thalassaemia Management, less awareness of Fucosidosis disease, and insubstantial treatment options are hampering the market growth. Furthermore, lack of health remuneration policies, rise in cost, and side effects associated with certain treatments are expected to hinder the market growth.

Region-Wise Insights

How is the Market for Transfusion Dependent Thalassaemia Management Market Turning Out in the Asia Pacific Region?

Improvement in healthcare spending propelling the growth of Transfusion Dependent Thalassaemia Management in Asia Pacific

The Asia Pacific is expected to exhibit a significant growth rate of all regions over the forecast period, with a CAGR of 5% during the forecast period. The growth is owed to increased awareness, significant increases in healthcare spending, and a rising frequency of the Transfusion Dependent Thalassaemia Management Market in the region. Asia Pacific is an emerging market due to the increase in point care approach to health & care. The increasing number of hospitals in India and China makes a promising market for the market worldwide.

In November 2020, for instance, researchers from numerous educational institutions based in China conducted a study to evaluate the prevalence of iron deficiency anemia and anemia in pregnant women. They found that nearly 13.9% of Chinese women were diagnosed with iron deficiency anemia, while around 19.8% were diagnosed with anemia. The increasing number of similar research studies in this country is anticipated to fuel the market.

What are the Factors Boosting the Market for Transfusion Dependent Thalassaemia Management in North America?

Technological Advancements Shaping Landscape for Transfusion Dependent Thalassaemia Management in North America

North America is anticipated to acquire a market share of about 25% in the forecast period. This growth is attributable to the rising prevalence of the condition in the region. As per the American Family Physician, the prevalence of iron deficiency anemia is about 20% in black and Mexican-American women, 9 to 12% in non-Hispanic white women, and nearly 2% in adult men. Approximately 9% of patients older than 65 years with this condition have gastrointestinal cancer. These numbers are estimated to grow in the near future, thereby propelling the market growth.

Government initiatives and an increase in the number of research partnerships are boosting market growth across North America. The United States of America leads the regional market owing to the rising awareness about the condition and the increasing number of populations with thalassemia carrier gene along with expanding birth rates due to variation of genes among the population.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-Wise Insights

By Treatment, Which Segment is Likely to Account for a Prominent Share?

Iron Chelating Drugs as an effective treatment to drive the market

According to the FMI analysis, the Increasing incidence of iron deficiency among individuals is expected to continue driving sales for iron chelating drugs over the forecast period. The increasing popularity of these drugs as an effective treatment along with the presence of innovative technologies and changing lifestyle patterns are other crucial factors augmenting the demand.

In May 2020, Luspatercept was suggested for authorization by the Committee for Medicinal Products for Human Use (CHMP) to treat anemia in both the rare blood condition beta type and the hematological malignancy myelodysplastic syndrome (MDS). Apart from this, some of the other approved chelating drugs in the USA include succimer, dimercaprol (BAL), edetate calcium disodium, deferoxamine, and penicillamine.

By End-user, Which Segment is Likely to Account for a Significant Share?

Hospitals to take the lead and drive market growth

According to the FMI analysis, Hospitals account for the largest market share. The requirement for several hospital stays and visits during the Transfusion Dependent Thalassaemia Management facilitates the growth of this segment. Hospitals are also emphasizing the delivery of various comprehensive programs with personalized and professional support in the management of target diseases. The ability of doctors to provide customers with personalized advice that would pertain to their specific circumstances and health needs will boost growth.

Market Competition

Key players in the Transfusion Dependent Thalassaemia Management Market are Celgene Corporation, BlueBird Bio, Protagonist Therapeutics, Agios Pharmaceuticals, Ionis Pharmaceuticals, Vifor Pharma, Sangamo Therapeutics, Orchard Therapeutics, CRISPR Therapeutics, and DisperSol Technologies among other global players.

  • In November 2022, the Centers for Disease Control and Prevention (CDC) launched a Thalassemia Healthcare Provider Resource Toolkit. This free toolkit is filled with free resources for providers caring for people living with thalassemia. It includes Continuing Medical Education Offerings and Webinars, Scientific Articles and Features, CDC Activities Related to Transfusion Complications in Thalassemia, Resources on Newborn Screening, Thalassemia Treatment Centers, Resources for Thalassemia Care, Treatment, and Management, and so on.
  • In August 2022, the USA Food and Drug Administration approved Zynteglo (Betibeglogene auto excel), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.

Report Scope

Report Attribute Details
Market Value in 2023 US$ 10 Million
Market Value in 2033 US$ 17.91 Million
Growth Rate CAGR of 6% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in USD Million and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
  • Treatment
  • End-User
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa
Key Countries Profiled
  • USA
  • Canada
  • Brazil
  • Argentina
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • Nordics
  • BENELUX
  • Australia & New Zealand
  • China
  • India
  • Association of Southeast Asian Nations
  • Gulf Cooperation Council
  • South Africa
Key Companies Profiled
  • Sigma-Aldrich. BD
  • Enzo Life Sciences
  • Creative Diagnostics
  • Thermo Fisher Scientific
  • Epitope Diagnostics Inc.
  • R&D Systems
  • QED Bioscience Inc
  • ACROBiosystems.
Customization Available Upon Request

Key Segments Profiled in the Transfusion Dependent Thalassaemia Management Industry Survey

Therapy:

  • Iron Chelating Drugs
  • Erythroid Maturation Agents
  • Stem Cell Therapy
  • Others

End-User:

  • Hospital
  • Homecare
  • Specialty Clinics
  • Others

Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Frequently Asked Questions

How the Gas Insulated Substation Market Developed in the Past?

From 2018 to 2022, the global market exhibited a 5.4% CAGR.

What is the Projected Size of the Transfusion Dependent Thalassaemia Management Market by 2033?

The global market size is estimated to reach US$ 17.91 billion by 2033.

Who are the Top Key Players in the Transfusion Dependent Thalassaemia Management Market?

R&D Systems and Creative Diagnostics are the top key players.

What is the Growth Potential of the Transfusion Dependent Thalassaemia Management Market?

The global market is estimated to secure a CAGR of 6% through 2033.

What Limits the Growth Potential of the Transfusion Dependent Thalassaemia Management Market?

Expensive treatment costs are likely to limit market growth.

Table of Content

1. Executive Summary | Transfusion Dependent Thalassaemia Management Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033

        5.3.1. Iron Chelating Drugs

        5.3.2. Erythroid Maturation Agents

        5.3.3. Stem Cell Therapy

        5.3.4. Others

    5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033

6. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Users

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By End Users, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End Users, 2023 to 2033

        6.3.1. Hospitals

        6.3.2. Clinics

        6.3.3. Others

    6.4. Y-o-Y Growth Trend Analysis By End Users, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By End Users, 2023 to 2033

7. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Europe

        7.3.4. Asia Pacific

        7.3.5. Middle East and Africa (MEA)

    7.4. Market Attractiveness Analysis By Region

8. North America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        8.2.1. By Country

            8.2.1.1. USA

            8.2.1.2. Canada

        8.2.2. By Treatment

        8.2.3. By End Users

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Treatment

        8.3.3. By End Users

    8.4. Key Takeaways

9. Latin America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Treatment

        9.2.3. By End Users

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Treatment

        9.3.3. By End Users

    9.4. Key Takeaways

10. Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Germany

            10.2.1.2. UK

            10.2.1.3. France

            10.2.1.4. Spain

            10.2.1.5. Italy

            10.2.1.6. Rest of Europe

        10.2.2. By Treatment

        10.2.3. By End Users

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Treatment

        10.3.3. By End Users

    10.4. Key Takeaways

11. Asia Pacific Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. China

            11.2.1.2. Japan

            11.2.1.3. South Korea

            11.2.1.4. Singapore

            11.2.1.5. Thailand

            11.2.1.6. Indonesia

            11.2.1.7. Australia

            11.2.1.8. New Zealand

            11.2.1.9. Rest of Asia Pacific

        11.2.2. By Treatment

        11.2.3. By End Users

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Treatment

        11.3.3. By End Users

    11.4. Key Takeaways

12. MEA Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. GCC Countries

            12.2.1.2. South Africa

            12.2.1.3. Israel

            12.2.1.4. Rest of MEA

        12.2.2. By Treatment

        12.2.3. By End Users

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Treatment

        12.3.3. By End Users

    12.4. Key Takeaways

13. Key Countries Analysis

    13.1. USA

        13.1.1. Pricing Analysis

        13.1.2. Market Share Analysis, 2022

            13.1.2.1. By Treatment

            13.1.2.2. By End Users

    13.2. Canada

        13.2.1. Pricing Analysis

        13.2.2. Market Share Analysis, 2022

            13.2.2.1. By Treatment

            13.2.2.2. By End Users

    13.3. Brazil

        13.3.1. Pricing Analysis

        13.3.2. Market Share Analysis, 2022

            13.3.2.1. By Treatment

            13.3.2.2. By End Users

    13.4. Mexico

        13.4.1. Pricing Analysis

        13.4.2. Market Share Analysis, 2022

            13.4.2.1. By Treatment

            13.4.2.2. By End Users

    13.5. Germany

        13.5.1. Pricing Analysis

        13.5.2. Market Share Analysis, 2022

            13.5.2.1. By Treatment

            13.5.2.2. By End Users

    13.6. UK

        13.6.1. Pricing Analysis

        13.6.2. Market Share Analysis, 2022

            13.6.2.1. By Treatment

            13.6.2.2. By End Users

    13.7. France

        13.7.1. Pricing Analysis

        13.7.2. Market Share Analysis, 2022

            13.7.2.1. By Treatment

            13.7.2.2. By End Users

    13.8. Spain

        13.8.1. Pricing Analysis

        13.8.2. Market Share Analysis, 2022

            13.8.2.1. By Treatment

            13.8.2.2. By End Users

    13.9. Italy

        13.9.1. Pricing Analysis

        13.9.2. Market Share Analysis, 2022

            13.9.2.1. By Treatment

            13.9.2.2. By End Users

    13.10. China

        13.10.1. Pricing Analysis

        13.10.2. Market Share Analysis, 2022

            13.10.2.1. By Treatment

            13.10.2.2. By End Users

    13.11. Japan

        13.11.1. Pricing Analysis

        13.11.2. Market Share Analysis, 2022

            13.11.2.1. By Treatment

            13.11.2.2. By End Users

    13.12. South Korea

        13.12.1. Pricing Analysis

        13.12.2. Market Share Analysis, 2022

            13.12.2.1. By Treatment

            13.12.2.2. By End Users

    13.13. Singapore

        13.13.1. Pricing Analysis

        13.13.2. Market Share Analysis, 2022

            13.13.2.1. By Treatment

            13.13.2.2. By End Users

    13.14. Thailand

        13.14.1. Pricing Analysis

        13.14.2. Market Share Analysis, 2022

            13.14.2.1. By Treatment

            13.14.2.2. By End Users

    13.15. Indonesia

        13.15.1. Pricing Analysis

        13.15.2. Market Share Analysis, 2022

            13.15.2.1. By Treatment

            13.15.2.2. By End Users

    13.16. Australia

        13.16.1. Pricing Analysis

        13.16.2. Market Share Analysis, 2022

            13.16.2.1. By Treatment

            13.16.2.2. By End Users

    13.17. New Zealand

        13.17.1. Pricing Analysis

        13.17.2. Market Share Analysis, 2022

            13.17.2.1. By Treatment

            13.17.2.2. By End Users

    13.18. GCC Countries

        13.18.1. Pricing Analysis

        13.18.2. Market Share Analysis, 2022

            13.18.2.1. By Treatment

            13.18.2.2. By End Users

    13.19. South Africa

        13.19.1. Pricing Analysis

        13.19.2. Market Share Analysis, 2022

            13.19.2.1. By Treatment

            13.19.2.2. By End Users

    13.20. Israel

        13.20.1. Pricing Analysis

        13.20.2. Market Share Analysis, 2022

            13.20.2.1. By Treatment

            13.20.2.2. By End Users

14. Market Structure Analysis

    14.1. Competition Dashboard

    14.2. Competition Benchmarking

    14.3. Market Share Analysis of Top Players

        14.3.1. By Regional

        14.3.2. By Treatment

        14.3.3. By End Users

15. Competition Analysis

    15.1. Competition Deep Dive

        15.1.1. Celgene Corp.

            15.1.1.1. Overview

            15.1.1.2. Product Portfolio

            15.1.1.3. Profitability by Market Segments

            15.1.1.4. Sales Footprint

            15.1.1.5. Strategy Overview

                15.1.1.5.1. Marketing Strategy

        15.1.2. BlueBird Bio

            15.1.2.1. Overview

            15.1.2.2. Product Portfolio

            15.1.2.3. Profitability by Market Segments

            15.1.2.4. Sales Footprint

            15.1.2.5. Strategy Overview

                15.1.2.5.1. Marketing Strategy

        15.1.3. Protagonist Therapeutics

            15.1.3.1. Overview

            15.1.3.2. Product Portfolio

            15.1.3.3. Profitability by Market Segments

            15.1.3.4. Sales Footprint

            15.1.3.5. Strategy Overview

                15.1.3.5.1. Marketing Strategy

        15.1.4. Agios Pharmaceuticals

            15.1.4.1. Overview

            15.1.4.2. Product Portfolio

            15.1.4.3. Profitability by Market Segments

            15.1.4.4. Sales Footprint

            15.1.4.5. Strategy Overview

                15.1.4.5.1. Marketing Strategy

        15.1.5. Ionis Pharmaceuticals

            15.1.5.1. Overview

            15.1.5.2. Product Portfolio

            15.1.5.3. Profitability by Market Segments

            15.1.5.4. Sales Footprint

            15.1.5.5. Strategy Overview

                15.1.5.5.1. Marketing Strategy

        15.1.6. Vifor Pharma

            15.1.6.1. Overview

            15.1.6.2. Product Portfolio

            15.1.6.3. Profitability by Market Segments

            15.1.6.4. Sales Footprint

            15.1.6.5. Strategy Overview

                15.1.6.5.1. Marketing Strategy

        15.1.7. Sangamo Therapeutics

            15.1.7.1. Overview

            15.1.7.2. Product Portfolio

            15.1.7.3. Profitability by Market Segments

            15.1.7.4. Sales Footprint

            15.1.7.5. Strategy Overview

                15.1.7.5.1. Marketing Strategy

        15.1.8. Orchard Therapeutics

            15.1.8.1. Overview

            15.1.8.2. Product Portfolio

            15.1.8.3. Profitability by Market Segments

            15.1.8.4. Sales Footprint

            15.1.8.5. Strategy Overview

                15.1.8.5.1. Marketing Strategy

        15.1.9. CRISPR Therapeutics

            15.1.9.1. Overview

            15.1.9.2. Product Portfolio

            15.1.9.3. Profitability by Market Segments

            15.1.9.4. Sales Footprint

            15.1.9.5. Strategy Overview

                15.1.9.5.1. Marketing Strategy

        15.1.10. DisperSol Technologies

            15.1.10.1. Overview

            15.1.10.2. Product Portfolio

            15.1.10.3. Profitability by Market Segments

            15.1.10.4. Sales Footprint

            15.1.10.5. Strategy Overview

                15.1.10.5.1. Marketing Strategy

16. Assumptions & Acronyms Used

17. Research Methodology

Recommendations

Healthcare

HIV/HBV/HCV Test Kits Market

Published : March 2023

Healthcare

Beta Thalassemia Testing Market

Published : November 2022

Healthcare

AIDS Related Primary CNS Lymphoma Market

Published : November 2022

Explore Healthcare Insights

View Reports

Transfusion Dependent Thalassaemia Management Market